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ABSTRACT 
The incorporation of chloroquine within nano formulations, rather than as a 
co-treatment of the cells, could open a new avenue for in vivo retinal gene 
delivery. In this manuscript, we evaluated the incorporation of chloroquine 
diphosphate into the cationic niosome formulation composed of poloxamer 
188, polysorbate 80 non-ionic surfactants, and 2,3-di (tetradecyloxy) 
propan-1-amine (hydrochloride salt) cationic lipid, to transfect rat retina. 
Niosome formulations without and with chloroquine diphosphate (DPP80, 
and DPP80-CQ, respectively) were prepared by the reverse phase 
evaporation technique and characterized in terms of size, PDI, zeta 
potential, and morphology. After the incorporation of the pCMS-EGFP 
plasmid, the resultant nioplexes -at different cationic lipid/DNA mass ratios- 
were further evaluated to compact, liberate, and secure the DNA against 
enzymatic digestion. In vitro procedures were achieved in ARPE-19 cells to 
assess transfection efficacy and intracellular transportation. Both nioplexes 
formulations transfected efficiently ARPE-19 cells, although the cell viability 
was clearly better in the case of DPP80-CQ nioplexes. After subretinal and 
intravitreal injections, DPP80 nioplexes were not able to transfect the rat 
retina. However, chloroquine containing vector showed protein expression 
in many retinal cells, depending on the administration route. These data 
provide new insights for retinal gene delivery based on chloroquine-
containing niosome non-viral vectors. 
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1. Introduction 
 
Retinal degeneration is a devastating ocular pathology caused by 
functional impairment of genes related mainly to the phototransduction 
process, the structure and metabolism of the retinal cells, and the 
maturation process of the mRNA needed to synthetize specific proteins. One 
of the most promising alternatives to treat retinal disorders like age-related 
macular degeneration [1], Leber congenital amaurosis (LCA) [2] retinitis 
pigmentosa [3] or choroideremia consists on the delivery of a normal copy 
of the mutated genes to the affected cells by means of gene therapy 
technology [4]. Since the success of first RPE65-gene-replacement trials for 
LCA type-2, further clinical trials of gene therapy have been conducted for 
other devastating retinal disorders [5]. In most of those clinical trials, viral-
vectors have been used to deliver the genetic material. Among them, 
adeno-associated virus (AAV) stand out for their safety profile [6]. In fact, 
Luxturna, the first gene therapy-based medicine approved by the FDA in 
2017 for the treatment of mutations in RPE65 gene linked to retinitis 
pigmentosa and Stargardt disease, is based on such AAV. However, the 
limited carrying capacity of genetic material, around 5kb, hampers their 
application to deliver genes that over pass such size to the retina. For 
instance, ABCA4 and MYO7A genes, whose mutations can be related to 
Stargardt disease and Usher Syndrome Type 1B, respectively [7], have a 
size of around 7kb. Therefore, the use of non-viral vectors represents an 
interesting alternative, since the size of DNA that can be inserted in some of 
these formulations is theoretically unlimited [8,9].  
 
Despite their limited transfection efficiency and transient gene 
expression, non-viral vectors have emerged as a promising alternative to 
deliver genetic material. Some of the main advantages of such gene 
delivery systems, in addition to their higher carrying capacity, include their 
low cost of production or their capacity to be easily modified in order to 
enhance their performance [10,11]. Hence, the research activity related to 
the design and characterization of novel non-viral vector formulations for 
gene delivery has considerably increased [12]. Cationic niosomes are self-
assembled vesicular nanovehicles, similar to liposomes, with encouraging 
properties for gene delivery applications. To mention a few, the chemical 
structure of niosomes makes it possible to provide more stable and less 
cytotoxic formulations at a low cost [13]. The amphiphilic nature of non-
ionic surfactants enable niosomes to trap both hydrophobic and hydrophilic 
compounds [14].The cationic part here is the hydrochloride salt of the 
cationic lipid 2,3-di (tetradecyloxy) propan-1-amine (D). Such cationic lipid 
contains the four pivotal components that manage the gene transfection 
process: a polar head, a backbone, a linker, and two non-polar tails [15]. 
 
One of the key limiting steps in the transfection process is the 
endosomal escape. Chloroquine is a known endosomal disrupting molecule 
and lysosomotropic agent that can cross the blood retinal barrier. Although 
chloroquine has been used in vitro as a pre-treatment of cultured cells to 
facilitate gene delivery [16], this study will be the first -to the best of our 
knowledge- to apply a chloroquine-containing niosome formulation in gene 
delivery setting. The incorporation of one or more of the materials at the 
molecular level, within the nano-formulation, can dramatically affect the 
transfection process under in vitro and in vivo conditions [12]. Thereafter, 
scientists may face a great challenge in the near future to test a library of 
different materials that can be incorporated within the gene delivery 
vehicles.  
 
Based on the aforementioned (D) cationic lipid, two niosome vehicles 
were formulated for retinal gene delivery with two non-ionic surfactants 
[polysorbate 80 (P80) and poloxamer 188 (P)], in the absence/ presence of 
chloroquine (CQ), referred as DPP80 and DPP80- CQ, respectively (Fig. 
1). The two vehicles were prepared by the emulsification/solvent 
evaporation system and characterized in terms of particle size, 
polydispersity index (PDI) and zeta potential. Then, the reporter pCMS-
EGFP plasmid was added at different weight ratios of cationic lipid to obtain 
nioplexes. Such DPP80/DPP80-CQ nioplexes were further characterized by 
size, PDI, charge, morphology, and the capability to compact, liberate and 
protect the DNA from digestive enzymes. In vitro comparative studies of 
both vehicles in ARPE-19 cells were achieved respecting their cellular 
uptake, transfection efficiency, viability and internalization mechanism. 
Finally, the two formulations were administered to rat eyes via intravitreal 
and subretinal injections, as a probe of concept, to estimate transfection 
efficiency by confocal microscopy. 
 
2. Materials and methods 
 
2.1. Production of cationic niosomes 
 
The synthesis of the hydrochloride salt form of the cationic lipid 2,3-di 
(tetradecyloxy) propan-1-amine (D) was performed as described in the 
literature, with slight modifications of the laboratory protocol [17]. 
Niosomes were composed by modified reverse-phase evaporation approach 
[18]. Concisely, 5 mg (0.1% w/v) of the lipid was dispersed in 1 ml of 
dichloromethane (organic phase). Subsequently, 5 ml milliQ water 
containing 12.5 mg (0.25% w/v) poloxamer 188 (P) (Sigma-Aldrich, 
Madrid, Spain), 12.5 mg (0.25% w/v) polysorbate 80 (P80) (Sigma-Aldrich, 
Madrid, Spain) and 2.5 mg (0.05% w/v) chloroquine diphosphate (CQ) 
(Sigma-Aldrich, Madrid, Spain) were added to the organic phase. The 
emulsions were obtained by sonication of the mixture for 50 s at 45W 
(Branson Sonifier 250®, Danbury, USA). Dichloromethane was eliminated 
from emulsions by dissipation under magnetic stirring for 2 h, rendering the 
cationic niosomes in the aqueous medium. The molar ratios of both DPP80 
and DPP80-CQ formulations were, 1.9/0.3/1.9 and 1.9/0.3/1.9/1, 
respectively. 
 
2.2. Plasmid propagation and elaboration of nioplexes 
 
The protocols for propagation, purification, and quantification of 
pCMS-EGFP plasmid (5541 bp, Plasmid Factory, Bielefeld, Germany), have 
been described previously [12]. The nioplexes (niosome/DNA complexes) of 
both DPP80 and DPP80-CQ were formed by mixing an adequate volume of 
pCMS-EGFP plasmid stock solution (0.5 mg/ml) with various amounts of the 
niosome suspension (1 mg cationic lipid/ml) to get different cationic 
lipid/DNA mass ratios (w/w). To enhance the electrostatic interaction, the 
nioplexes mixture was allowed to settle for 30 min at room temperature. 
 
 
 
Fig. 1. Chemical structure of the components of DPP80 and DPP80-CQ 
niosomes. (A) Polysorbate80, (B) Chloroquine diphosphate salt, (C) 
Poloxamer188 and (D) cationic lipid (DTPA-Cl).  
 
2.3. Characterization of niosomes/nioplexes 
 
Dynamic light scattering (DLS) technique was used to estimate both 
particle size and polydispersity index (PDI) measurements (Malvern 
Zetasizer Nano ZS, UK). Particle size, was determined by cumulative 
analysis of the recorded hydrodynamic diameter. Laser Doppler Velocimetry 
(LDV) was used to assess zeta potential (ZP). Samples were dispersed in a 
0.1mM NaCl solution. Triple measurements were carried out for all samples. 
The morphology of both niosomes and nioplexes was estimated by 
transmission electron microscopy (TEM). Shortly, onto glow-discharged 
carbon coated grids, 5 μl sample was allowed to adhere on the surface for 
60 s. Samples were examined under TEM, Tecnai G2 20 Twin (FEI, 
Eindhoven, The Netherlands). In a bright-field image mode, the operation 
was done with an accelerating voltage of 200 keV. Digital images were 
captured by an Olympus SIS Morada digital camera. Niosomes' ability to 
compact, liberate and safeguard DNA from enzymatic digestion was 
assessed by agarose gel electrophoresis studies. Nioplexes samples (200 
mg of plasmid DNA/20 μl) were compared to naked (uncomplexed) DNA. 
The agarose gel (0.8% w/v) was immersed in a Tris–acetate–EDTA buffer, 
and the DNA samples were run on the gel for 30 min at 120 V. Next, 
agarose gel was stained with GelGreen®. A digital ChemiDoc™ MP Imaging 
System (Bio-Rad, Madrid, Spain) was used for band observation. 20 μl of a 
2% SDS solution (Sigma-Aldrich, Madrid, Spain) was added to the samples 
to estimate the liberation of DNA from both DPP80 and DPP80-CQ 
vehicles at different cationic lipid/DN mass ratios. In addition, DNase I 
(Sigma- Aldrich, Madrid, Spain) was added at a concentration of 1 unit of 
DNase I/2.5 μg DNA to evaluate the protective ability of both vehicles 
against enzymatic digestion. Then, the samples were incubated at 37 °C for 
30 min and a 2% SDS solution was added to evaluate if released the DNA 
from the vehicles wad protected from the enzymatic digestion. 
 
2.4. In vitro transfection experiments 
 
ARPE-19 cells, purchased from the American Type Culture Collection 
(ATCC, CRL 2302®), were seeded in 24-well plates at a density of 8×104 
cells/well, with 500 μl of complete medium, formed of D-MEM/F-12 
containing 10% fetal bovine serum (Gibco®, California, USA). Then, at a 
confluence level of 70–80%, the media was removed, and cells were 
exposed to nioplexes at different cationic lipid/DNA mass ratios (w/w) (1.25 
μg DNA/well) dispersed in serum free Opti-MEM® solution (Gibco®, 
California, USA) at 37 °C for 4 h. Subsequently, transfection medium was 
removed, and cells were thoroughly washed 3 times with PBS. Then, cells 
were cultured in 1 ml of complete medium and allowed to grow for further 
72 h until fluorescence microscopy imaging (Nikon TSM) and flow cytometry 
analysis (FACSCalibur™, BD Biosciences, USA) were done. FL1 (530/30) 
was used to detect EGFPexpressing transfected cells, and FL3 (670) was 
used to detect Propidium Iodide-stained dead/dying cells. Untransfected 
cells were used as negative control for all experiments, while cells 
transfected with Lipofectamine™ 2000 (Invitrogen, California, USA), 
according to manufacturer's protocol, were considered as positive controls. 
10.000-gated events were acquired and analyzed using Flowing Software 
2.5.1. Data represent the mean (±SD) of three independent experiments, 
each of them performed in triplicate. 
 
2.5. Cellular uptake and endocytosis mechanism studies 
 
FITC-labeled (pCMS-EGFP) plasmid (DareBio, Madrid, Spain) was 
used instead of pCMS-EGFP plasmid to estimate the cellular uptake of the 
vehicles. The same protocol described in the previous 2.4 section, was used 
to incubate and maintain ARPE-19 cells, and to evaluate cellular uptake. 
After removal of the transfection medium and multiple washes of the plates 
with PBS, the cells were assayed by FACSCalibur flow cytometer. The 
negative control cells were transfected with naked DNA, and the percentage 
of FITC-positive cells represented the cellular uptake values. Each specimen 
was assayed in triplicate. Different uptake inhibitors were used to estimate 
the endocytosis mechanism of vehicles. Genistein, chlorpromazine 
hydrochloride, methyl-β-cyclodextrin and wortmannin were used as 
inhibitors for caveolae-mediated endocytosis (CvME), clathrin-mediated 
endocytosis (CME), both (CvME and CME) and macropinocytosis (MPC), 
respectively. Nioplexes at 10/1 cationic lipid/DNA mass ratio were 
complexed with pCMS-EGFP plasmid, and followed the same protocol 
described in the previous 2.4 section to transfect ARPE-19 cells. Prior to the 
addition of nioplexes, cells were incubated with either 200 μM genistein for 
30 min, or with 5mM methyl-β-cyclodextrin, 50 nM wortmannin, or with 5 
μg/ml chlorpromazine hydrochloride for 60 min. Cells were incubated with 
serum-free Opti-MEM® solution for 4 h at 37 °C. Subsequently, cells were 
carefully washed with PBS after removal of the transfection medium. Then, 
complete medium was added, and cells were incubated to grow for a further 
72 h until flow cytometer analysis was done to determine the transfection 
efficiency. Each specimen was analyzed in triplicate. 
 
2.6. Buffering capacity of niosomes 
 
The buffering capacity of both DPP80 and DPP80-CQ niosomes was 
assayed by volumetric analysis. Briefly, 10 ml formulation samples were 
titrated with aliquots of 100 μl 0.1M HCl solution, and the changes in pH 
value were monitored by a pH meter (CRISON, GLP 21, Barcelona, Spain). 
 
2.7. In vivo studies 
 
Intravitreal (4 μl containing 100 ng of pDNA) and subretinal injection 
(1 μl containing 25 ng of pDNA) of both DPP80 and DPP80-CQ nioplexes 
suspension were performed into four adult female Sprague–Dawley rats (6–
7 weeks old, 200–300 g weight) per formulation. Experiments were done 
according to the Spanish and European Union regulations for the use of 
animals in research and the Association for Research in Vision and 
Ophthalmology (ARVO) statement, as described in the literature [12]. To 
deliver nioplexes to the subretinal space, a bent 33-gauge needle was 
introduced through a sclerotomy (1–2 mm) posterior to ora serrata and in a 
tangential direction toward the posterior retinal pole along the subretinal 
space. Successful administration was confirmed by the appearance of a 
partial retinal detachment by direct ophthalmoscopy of the eye fundus 
through the operating microscope (Zeiss OPMI® pico; Carl Zeiss Meditec 
GmbH, Jena, Germany). The untreated right eyes were injected only with 
the vehicles and served as negative controls. 
 
Rats were sacrificed and perfused with 4% paraformaldehyde (PFA) 
after 72 h and eyes were removed, opened at the cornea and immersed in 
PFA. For whole mounts, retina was dissected from the eyecup and flattened 
onto Superfrost glass slides (Superfrost Plus, Fisher Scientific). For 
cryosections, the eyes were cryoprotected in sucrose and embedded in 
Tissue-Tek® OCT (optimum cutting temperature). The eyes were 
cryosectioned at 16 μm and transferred directly onto microscope slides 
(Superfrost, Fisher Scientific). 
 
For immunohistochemistry, whole mounts or retinal sections were 
washed and blocked with 10% bovine serum albumine and 0,05% triton in 
PBS for 1 h (cryosections) or 2 h (whole mounts). Both sections and whole 
mounts were incubated overnight at 4 °C with primary antibodies: rabbit 
anti-NeuN (Merck Millipore, MA, USA), rabbit anti-recoverin (Merck Millipore, 
MA, USA), rabbit anti-Protein kinase C (PKC, Santa Cruz Biotechnology) and 
rabbit anti-GFAP (Santa Cruz Biotechnology). Samples were rinsed and 
incubated with Alexa Fluor 555 donkey anti rabbit (Thermofisher Scientific) 
and counterstained with Hoechst 33342 (Thermofisher Scientific). Finally, 
whole mounts and sections were mounted with antifade mounting meédium 
and evaluated with a Leica TCS SPE spectral confocal microscope (Leica 
Microsystems GmbH, Wetzlar, Germany). 
 
2.8. Statistical analysis 
 
INSTAT program (GraphPad Software, San Diego, CA, USA) was used 
to perform the statistical analysis. Differences between groups at 
significance levels of 95% were calculated by the ANOVA and the Student's 
t-test. In all cases, P values < .05 were regarded as significant. Normal 
distribution of samples was assessed by the Kolmogorov-Smirnov test and 
the homogeneity of the variance by the Levene test. Numerical data were 
presented as mean ± SD. 
 
Table 1. Physical features of both DPP80 and DPP80-CQ niosomes in 
terms of size (nm), Polydispersity index (PDI), and zeta potential (mV). The 
values exemplify the mean ± SD (n=3). 
 
 
 
3. Results 
 
3.1. Characterization of niosomes/nioplexes 
 
Both niosome vehicles were prepared by mixing [polysorbate 80 
(P80) and poloxamer 188 (P)] non-ionic surfactants and cationic lipid (D). 
In the absence/presence of chloroquine (CQ), niosomes were referred as 
DPP80, or as DPP80-CQ, respectively (Fig. 1). Both niosomes were 
prepared by the emulsification/solvent evaporation method and were 
characterized in terms of particle size, zeta potential (ZP) and polydispersity 
index (PDI) as shown in Table 1. The incorporation of chloroquine into the 
DPP80 niosome formulation increased the size of those niosomes from 90 to 
118 nm. Moreover, upon chloroquine addition, the ZP values decreased 
remarkably to 29 mV in DDP80-CQ niosomes compared to 44 mV in 
DPP80 niosomes. Interestingly, the addition of chloroquine also decreased 
the PDI value from 0.42 in DPP80 formulation to 0.13 in DPP80-CQ 
formulation.  
 
Fig. 2 illustrates the physicochemical characterization of DPP80 and 
DPP80-CQ nioplexes. In Section 2-A, the size and ZP values of both 
nioplexes at different ratios (from 4/1 to 12/1) can be observed. The size of 
DPP80 nioplexes (light bar) generally decreased, with fluctuations, 
between 170 nm at 4/1cationic lipid/DNA mass ratio to 106 nm at 12/1 
mass ratio. With respect to the size of DPP80-CQ nioplexes (dark bars), it 
depicted an evident decreasing pattern (from 300 nm at 4/1 to 140 nm at 
12/1 cationic lipid/DNA mass ratios). Basically, the addition of chloroquine 
to the formulation increased the sizes at all cationic lipid/DNA mass ratios, 
in comparison to DPP80 nioplexes. Regarding the ZP, at all cationic 
lipid/DNA mass ratios, readings of DPP80 nioplexes (light lines) exceeded 
their DPP80-CQ counterparts (dark lines). Concerning the PDI values 
(Supplementary data, Table. 1), except for the 4/1 cationic lipid/DNA mass 
ratio, the PDI values of DPP80 nioplexes surpassed those of DPP80-CQ. 
As depicted in Fig. 2- B1, the morphology of DPP80 nioplexes by TEM, 
revealed distinct imperfectly spherical structure, while DPP80-CQ nioplexes 
morphology showed aggregated lamellar morphology (Fig. 2-B2). Fig. 2-C 
represents the agarose gel electrophoresis assays of both DPP80 (C1) and 
DPP80- CQ (C2) nioplexes prepared at different cationic lipid/DNA mass 
ratios (4/1, 6/1, 8/1 and 10/1). At all cationic lipid/DNA ratios, both 
niosomes were able to condense the DNA, since clear white bands were 
recognized in wells 4, 7, 10, and 13. However, in the case of DPP80-CQ 
(C2) dim supercoiled (SC) bands were noticed on 7, 10, and 13 wells. Upon 
SDS addition, the DNA was successfully released from both formulations at 
all cationic lipid/DNA ratios evaluated, since clear SC bands were observed 
on lanes 5, 8, 11, and 14. Furthermore, the DNA bound to the surface of 
both niosome structures was shielded from enzymatic digestion, as clear SC 
bands were observed on lanes 6, 9, 12, and 15. No SC bands were detected 
on lane 3, which proves that the plasmid DNA can be fully digested by the 
DNase I enzyme. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2. Physicochemical features of nioplexes. (A) The impact of cationic 
lipid/DNA mass ratio (w/w) on the size (bars) and zeta potential (lines). The 
data represent the mean ± SD (n=3). TEM images of DPP80 (B1) and 
DPP80-CQ complexes (B2) at 8/1 and 10/1cationic lipid/DNA mass ratio 
(w/w) respectively. Scale bar=200 nm. (C) condensation, release by SDS 
and DNase I protection of DNA at various cationic lipid/DNA mass ratios 
(w/w) of nioplexes based on DPP80 (C1) and DPP80-CQ (C2) vehicles 
depicted by agarose gel electrophoresis. Lanes 1–3 represent uncondensed 
DNA; lanes 4–6, cationic lipid/DNA mass ratio 4/1; lanes 7–9, cationic 
lipid/DNA mass ratio 6/1; lanes 10–12, cationic lipid/DNA mass ratio 8/1; 
lanes 13–15, cationic lipid/DNA mass ratio 10/1. Complexes were processed 
with SDS (lanes 2, 5, 8, 11 and 14) and DNase I+SDS (lanes 3, 6, 9, 12 
and 15). OC: open circular structures, SC: supercoiled structures. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3. In vitro transfection and viability performance of both DPP80 and 
DPP80-CQ nioplexes in ARPE-19 cells. (A) The percentage of EGFP-positive 
cells (bars) and the percentage of viable cells (lines) at various cationic 
lipid/DNA mass ratios (w/w) evaluated by flow cytometry at 72 h. Data are 
expressed in terms of mean ± SD, n=3. L2K=Lipofectamine™2000. *P < 
.05 compared to DPP80, #P < .05 compared to nioplexes. (B1 and B2) 
fluorescence and phase-contrast overlay micrographs of ARPE-19 cells after 
72 h transfection at 8/1 and 10/1 cationic lipid/DNA mass ratios (w/w) for 
DPP80 and DPP80-CQ, respectively. Scale bar=100 μm. 
 
 
3.2. In vitro transfection and viability studies in ARPE-19 cells 
 
Fig. 3-A depicts the transfection efficiency and cell viability of cationic 
niosome/DNA nioplexes in ARPE-19 cells. Cationic lipid/DNA mass ratios 
(w/w) higher than 4/1 showed about 20–30% of cells transfected by both 
DPP80 and DPP80-CQ nioplexes. However, the values of ARPE-19 cells 
transfected by DPP80 nioplexes at 6/1, 8/1 and 12/1 cationic lipid/DNA 
mass ratios (light bars) were significantly higher that values obtained at 
those same rations when ARPE-19 were transfected with DPP80-CQ (dark 
bars) formulation. In any case, transfection values for both formulations 
were significantly lower (p < .05) than those values gained with 
Lipofectamine™2000 (36.6%). Meantime, naked DNA plasmid did not show 
any transfection (data not shown). Regarding cell viability, all cationic 
lipid/DNA mass ratios (w/w) studied above 6/1, had obviously revealed 
higher percentages of viability with DPP80-CQ nioplexes compared to their 
DPP80 counterparts. The viability value of cells transfected with DPP80-CQ 
at 10/1 cationic lipid /DNA mass ratio (90%) was similar to the viability 
value obtained with Lipofectamine™ 2000 commercial reagent (89.5%). The 
micrographs observed in Fig. 3-B1 for DPP80, and in Fig. 3-B2 for DPP80-
CQ nioplexes, confirmed the previously mentioned difference in the viability 
of transfected ARPE- 19 cells with both nioplexes at 8/1 and 10/1 cationic 
lipid/DNA mass ratios respectively. 
 
3.3. Cellular uptake studies 
 
Fig. 4-A illustrates the cellular uptake study of both DPP80 and 
DPP80-CQ nioplexes with FITC-labeled pDNA in ARPE-19 cells carried out 
by flow cytometry. Nioplexes at the cationic lipid/DNA mass ratio of the 
highest transfection efficiency, 8/1 and 10/1 for DPP80 and DPP80-CQ 
respectively, were used to evaluate the uptake percentage after 4 h of 
incubation. The uptake values of DPP80 and DPP80-CQ were 73.60% and 
74%, respectively. 
 
3.4. The impacts of endocytosis inhibitors on cellular transfection 
 
Fig. 4-B shows cellular transfection of pCMS-EGFP plasmid, mediated 
by DPP80 (light bars) and DPP80-CQ (dark bars) nioplexes, in ARPE-19 
cells with different endocytosis inhibitors. The transfection results were 
calculated as percentages from the absolute transfection values obtained by 
DPP80 and DPP80-CQ nioplexes at 8/1 and 10/1 cationic lipid/DNA mass 
ratios, respectively, in the absence of endocytosis inhibitors. Transfection 
efficiency of both nioplexes was slightly affected by the caveolae inhibitor, 
genistein (transfection values were about 93% for both DPP80 and 
DPP80-CQ), without statistically significant difference between both 
nioplexes (p ˃ 0.05). Additionally, selective inhibition of CME (by 
chlorpromazine hydrochloride) had a more pronounced effect on DPP80 
nioplexes than on DPP80-CQ (p ˂ 0.05) (the normalized values of 
transfection were 67% and 89%, respectively). Nevertheless, transfection 
efficiency was more affected by methyl-β-cyclodextrin (inhibitor of both 
CME and CvME) (transfection values decreased to be 11% and 23% for 
DPP80 and DPP80-CQ nioplexes without inhibition, respectively). 
Interestingly, wortmannin, an inhibitor of MPC, had statistically reduced the 
normalized transfection efficiency of DPP80-CQ nioplexes (to be 57%) 
when compared to DPP80 counterparts (75%). 
 
3.5. Buffering capacity of niosomes 
 
Fig. 4-C shows the buffering capacity of both DPP80 and DPP80-CQ 
niosomes. After addition of successive volumes (100 μl) of a 0.1M HCl 
aqueous solution to a fixed volume of niosomes (10.000 μl), the pH titration 
curve revealed that DPP80-CQ had a considerably higher buffering capacity 
than DPP80, whereas the initial pH values of both formulations were 
around 4. 
 
3.6. In vivo study 
 
3.6.1. Histological assessment after subretinal injections 
 
At 10/1 cationic lipid /DNA mass ratio, DPP80-CQ nioplexes were 
administered subretinally. After 72 h, EGFP expression in rat retinae was 
analyzed by CLSM (Fig. 5). In retinal cross sections, EGFP protein 
expression was recognized in GCL (Fig. 5-A, and B, white arrows). 
Interestingly, EGFP expression was also observed in some photoreceptor 
cells (Fig. 5-A, and C, yellow arrows). Such EGFP expression colocalized 
with some recoverin positive photoreceptors (Fig. 5-B, yellow arrows). 
Transfection of DPP80-CQ nioplexes on photoreceptors after subretinal 
administration was also observed on Supplementary Fig. 3 (pink arrows). 
Additionally, blue arrows observed in Fig. 5-D suggest that some damaged 
and displaced RPE cells were transfected close to the injection site. It is 
worth mentioning that no co-localization was observed in the bipolar cells 
stained with PKC. No fluorescence was detected in the retinae injected with 
the vehicle (Supplementary Fig. 4-C). 
 
 
 
 
 
Fig. 4. Cellular uptake and internalization studies of both DPP80 and 
DPP80-CQ nioplexes at 8/1 and 10/1 cationic lipid/DNA mass ratio. (A) 
Flow cytometry histograms representing the FITC-labeled plasmid uptake in 
ARPE-19 cells after 4 h of incubation. (B) Endocytic inhibitors effect on the 
transfection performance of DPP80 and DPP80-CQ nioplexes. The values 
were normalized to the transfection without inhibitor. *P < .05 (C) pH 
buffering capacity analysis of DPP80 and DPP80-CQ niosomes. 
 
 
3.6.2. Histological assessment after intravitreal injections 
 
Fig. 6 revealed some EGFP expression in whole mount sections of the 
retina in both GCL (Fig. 6-A, white arrows) and INL (Fig. 6-B, yellow 
arrows), close to the injection site. According to the morphology and the 
retinal layer examined, such fluorescence could correspond to ganglion and 
amacrine transfected cells. In any case, endothelial cells migrating to the 
injection site or glial cells could also have been transfected. Transfection in 
the GCL was also observed in retinal crosssections (Fig. 6-D, white arrows) 
and, interestingly, in the OPL (Fig. 6- C, blue arrows).  
 
After both intravitreal and subretinal injections, we did not observe GFP 
expression in regions distal from the injection sites (Fig. 4-A, B, 
Supplementary data). 
 
 
 
 
Fig. 5. Retinal cross sections micrographs obtained by confocal microscopy 
3 days post subretinal injection of DPP80-CQ nioplexes (A–D). EGFP 
protein was observed mainly in GCL (white arrows), photoreceptors (yellow 
arrows) and RPE cells (blue arrows). Retinal sections were stained with 
antibodies against NeuN(A), recoverin (B, D) and protein kinase C (C). The 
cell nuclei were counterstained with Hoechst 33342. GCL, ganglion cell 
layer; INL, inner nuclear layer; ONL, outer nuclear layer; OS, photoreceptor 
outer segment Scale bars: 20 μm. (For interpretation of the references to 
colour in this figure legend, the reader is referred to the web version of this 
article.) 
 
4. Discussion 
 
In this research work, we offer a novel approach to design, 
characterize and evaluate chemical vectors for retinal gene delivery. More 
precisely, we evaluated the role of chloroquine incorporation into niosomes 
composed of cationic lipid and a mixture of non-ionic surfactants.  
 
Chloroquine, by itself, can enhance transfection efficiency whenever 
included to the cell culture medium or incorporated into cationic peptide- 
DNA complexes [19] in a dose-dependent matter. However, the pre-
treatment with chloroquine, has shown high toxicity levels that limit further 
clinical applications [20]. To avoid such noxious effect, in the current study, 
chloroquine was incorporated within the niosome formulation. Such 
inclusion of chloroquine into a niosome formulation, rather than as a co-
/pre-treatment of cells, would be a more logical approach for in vivo 
settings. The amphiphilic nature of both non-ionic surfactants used (P80 
and P) can deliver both hydrophilic and lipophilic molecules. Interestingly, 
propylene oxide chains of the P can interact with lipid membranes and 
induce their structural re-arrangement for better stability and translocation 
of the gene carriers [21]. In addition, the incorporation of P to polycation-
DNA complexes enhanced the expression level of the delivered genes in 
both in vitro and in vivo conditions at doses below the known toxicity levels 
[22]. P80 has been reported to act as a co-emulsifier along with P, in drug 
and gene delivery endeavors [23]. Moreover, the encouraging properties of 
P80 create a steric barrier that evades the aggregation of nano-vesicles, 
enhances the cell tolerance [11], and improves transfection efficiency due 
to the presence of polyethylene glycol (PEG) chains in its structure [24]. 
However, the ability P to form network structures might be more suitable 
than P80, if used with water-soluble cationic lipids, to enhance their 
flexibility and durability [25]. In such case, a mixture of two specific types 
of non-tensioactive molecules could provide a synergistic enhancement of 
nano-vesicle stabilization [26].  
 
Regarding the cationic lipid, the high solubility of the D-Cl salt 
enhances biodistribution of lipid/plasmid complexes, and therefore, 
transfection efficiency [27]. However, in a previous study, we observed that 
the solubility of cationic lipid can dramatically shift the transfection results 
according to the type of the cells and the way of formulation. In that study, 
the DTPA cationic lipid (non-salt form) succeeded to transfect retinal cells in 
vitro conditions [11], while in such mentioned study, the salt form failed to 
transfect retinal cells in vivo. Interestingly, the same formulation with the 
same salt form of cationic lipid (DPP80) succeeded to transfect cerebral 
cortical cells in vivo [28]. Strikingly, both salt/non-salt forms of the cationic 
lipid were able to transfect ARPE-19 cells in vitro conditions. In any case, 
the non-salt form was superior in terms of transfection and cell viability. 
This contradiction emphasizes the lack of correlation between the in vivo 
and in vitro transfection conditions and the importance of the formulation at 
physical level. 
 
To emphasize the impact of chloroquine, DPP80 and DPP80-CQ 
niosomes were elaborated and compared. The characterization data of both 
niosomes were analyzed (Table 1). The incorporation of chloroquine slightly 
increased the size of niosomes by about 28 nm, and reduced both PDI 
(about 69% decrease) and ZP (about 34% decrease). Drug/gene delivery 
vehicles are generally favored by small polydispersity values [29]. The 
positive ZP values (> +25 mV) detected for both niosomes would reflect a 
potentially long-lasting stability. Once the niosomes were characterized in 
terms of size, PDI, and zeta potential, nioplexes were elaborated with the 
pCMS-EGFP plasmid at various cationic lipid/DNA mass ratios by adding the 
reporter plasmid to the niosomes and not the opposite to ensure proper 
condensation process [30]. The ZP of DPP80 nioplexes was clearly lower 
when compared to the same niosomes without chloroquine (Fig. 2-A). On 
the other hand, ZP of chloroquine-containing nioplexes (DPP80-CQ) 
oscillated within a narrower range (19–25 mV) in comparison to DPP80- 
CQ niosomes (29 mV). Generally, the compaction of DNA is improved when 
90% of the charge is compensated in an aqueous solution [31]. Strikingly, 
at 8/1 and 10/1 mass ratios for DPP80 and DPP80-CQ, respectively, ZP 
values fluctuated within a narrow range (23–27 mV) which represents a 
small reduction in ZP for DPP80-CQ compared to ZP of niosomes (29 mV). 
This suggests a spontaneous electrostatic interaction of pDNA with DPP80-
CQ niosomes at 10/1 mass ratio which could be explained by a direct 
interaction of chloroquine with pDNA. Regarding PDI values of nioplexes, an 
obvious effect of chloroquine addition at all ratios studied above 4/1 was 
observed, as PDI values decreased in comparison to DPP80 formulation 
(Supplementary Table 1). The electron micrographs illustrated a discrete, 
almost spherical morphology and absence of aggregates in DPP80 
complexes (Fig. 2-B1). By contrast, DPP80-CQ nioplexes appeared as 
clusters of multilamellar planar structures that form string-like colloidal 
aggregates (Fig. 2-B2). The lamellar spacing was around 5.5–6 nm, 
suggesting that the pDNA strands were complexed with the cationic lipid 
bilayers [15]. Similarly, many mixtures of neutral lipids (as DOPC and 
DOPE), along with cationic lipids (as DOTAP), extensively used for gene 
delivery purposes, are known to form lamellar complexes with DNA [32]. 
 
The agarose gel retardation assay showed that both niosomes, at all 
studied cationic lipid/DNA ratios, were able to condense, release and protect 
the DNA from enzymatic digestion (Fig. 2-C). Of note, the relatively lower 
DNA condensation, observed by the chloroquine-containing formulation (Fig. 
2-C2), did not hamper the release or the protection of the condensed DNA, 
which is of utmost importance during the transfection process. Any change 
in condensation efficiency might affect the pattern and topology of spatial 
DNA configuration. Even more, the state of DNA condensation can be 
affected by both the type and the content of the surfactant or other 
additives as chloroquine. Therefore, the fine-tuning of such molecules could 
be of importance to unveil the mechanism of condensation of different types 
of DNA molecules within different nano-vesicles. Even at high 
concentrations of chloroquine, 100 μg/ml, ARPE-19 cells appeared healthy 
with good viability, despite the appearance of many vacuoles in the 
cytoplasm (Supplementary Fig. 1). The transfection efficiency in vitro, 
ARPE-19 cells, fluctuated within a small range in both vectors at all mass 
ratios studied (Fig. 3). However, the cell viability was in favor of DPP80-CQ 
(Fig. 3-A). Noteworthy, chloroquine inhibits lysosomal enzymes by 
increasing the pH of the lysosomes and disturbing their fusion with 
autophagosomes, thus inhibits autophagy [33]. Moreover, chloroquine and 
its autophagy inhibiting derivative, hydroxychloroquine, are both FDA-
approved agents [34]. According to the cell type or the state of stress, 
autophagy might protect or promote cell death in the eye [35]. This 
mutable nature of autophagy might be the reason for the increased cell 
viability observed with DDP80-CQ formulation in comparison with its 
chloroquine-free counterpart, DPP80. Generally, cell viability and 
metabolism of ARPE-19 cells are relatively unaffected by the concentrations 
of chloroquine between 10 and 30 μg/ml, though affected in a dosage-
dependent fashion afterward [36]. To analyze whether the enhanced cell 
internalization of nioplexes was among the effects that chloroquine could 
have on niosome formulations, we determined the percentage of ARPE-19 
cell uptake of both DPP80 and DPP80-CQ formulations at the mass ratios 
of best transfection efficiency, 8/1 for DPP80 and 10/1 for DPP80-CQ (Fig. 
4). Interestingly, flow cytometry studies showed that chloroquine 
incorporation had an insignificant effect on the percentage of cellular uptake 
when compared to the DPP80 formulation (Fig. 4-A). Such observation is 
most probably due to the indifferent surface charge of both nioplexes at the 
aforementioned mass ratios (22.5 ± 7.3 and 25.3 ± 2.5 for DPP80 and 
DPP80- CQ, respectively, P > .05). The similar uptake percentages in such 
ratios could justify the unaltered transfection results depicted previously 
(Fig. 3-A). The transfection efficiency can be markedly affected by the 
mechanism of endocytosis. Consequently, we studied three of the most 
active cellular internalization pathways: clathrin-mediated endocytosis 
(CME), caveolae-mediated endocytosis (CvME) and micropinocytosis (MPC). 
The results observed in Fig. 4-B suggested that DPP80-CQ nioplexes were 
internalized mainly by MPC, while CvME and CME had less participation in 
the cellular uptake process. Due to its ability to internalize larger structures, 
macropinocytosis pathway has been proposed to mediate the internalization 
of non-viral gene delivery vehicles [37]. Moreover, MPC is considered as the 
major pathway responsible for DNA transfection in certain cell types [38]. In 
contrary, DPP80 nioplexes were internalized mainly by CME and, to a lesser 
extent, by MPC, while CvME had a much less participation in the cellular 
uptake process. However, the minor fluctuation in transfection efficiency 
between the two nioplexes could be due to limited variations between the 
two main different mechanisms of internalization (CME for DPP80 and MPC 
for DPP80-CQ). The delivery of genetic material by CvME and CME passes 
through late endosomes/lysosomes, which increases the hazards of DNA 
degradation and lowers the transfection efficiency [39]. So, an expected 
trivial effect of CvME and especially CME pathways could explain the high 
percentages of EGFP expression in ARPE cells by both nioplexes (Fig. 3), 
compared to lipofectamine® 2000 (approximately, 80% and 75% of 
lipofectamine®2000 for DPP80 and DPP80-CQ, respectively). 
 
Afterwards, we analyzed the pH-buffering capacity of both niosomes 
(Fig. 4-C). The incorporation of chloroquine into the niosome formulation 
increased the pH-buffering capacity upon titration with 0.1M HCl, compared 
to the niosomes elaborated without chloroquine (at pH values > 2). Though, 
there was no change in the buffering capacity when the pH was<2 for both 
niosomes. Chloroquine might induce endosomal and lysosomal escape via 
the proton sponge effect [40]. This result could suggest that chloroquine-
containing formulation could increase the proton sponge effect, and 
therefore, the endosomal escape capacity of DPP80-CQ niosomes. 
However, as the predominant mechanism of internalization for DPP80-CQ 
was neither CvME nor CME, the impact of the proton sponge effect of 
chloroquine on the transfection efficiency was insignificant. 
 
Based on the previously mentioned physicochemical and in vitro 
biological results, we were enthusiastic to perform a preliminary in vivo 
study to evaluate the transfection efficiency of our formulations, DPP80-CQ 
in particular, in rat retinae after both subretinal (Fig. 5), and intravitreal 
injections (Fig. 6). Subretinal injection is a well-known clinical route to 
deliver genetic/drug material to the back of the eye. In addition, it enables 
direct contact of the injected nucleic acids with the outer retinal layers, 
photoreceptors and RPE cells. Noteworthy, clinical trials to treat many 
inherited retinal diseases such as LCA type 2 used the subretinal injection 
route [41]. However, it is less desirable than the intravitreal route due to 
the possible complications; such as retinal detachment or the localized side 
effects around the site of injection. Generally, IV injection is more widely 
applicable in the clinical practice due to its ability to deliver genetic material 
to a larger retinal surface, in addition to less surgical trauma compared to 
the SR route [42].  
 
 
 
Fig. 6. Confocal fluorescence micrographs of whole mount (A, B) and cross-
sections (C, D) of the retina 3 days after intravitreal administration of 
DPP80-CQ nioplexes. EGFP expression can be observed in both GCL (A, C 
and D, white arrows) and INL (B and C, yellow arrows). Interestingly, some 
protein expression was also observed in OPL (C, blue arrows). Whole mount 
and retinal sections were stained with NeuN (A-D). The cell nuclei were 
counterstained with Hoechst 33342 (blue). GCL, Ganglion cell layer; INL, 
inner nuclear layer; ONL, outer nuclear layer; OPL, outer plexiform layer. 
Scale bars: 20 μm. (For interpretation of the references to colour in this 
figure legend, the reader is referred to the web version of this article.) 
 
 
 
 
Surprisingly, DPP80 did not induce any transfection to retinal cells in 
vivo after both subretinal or intravitreal injections (Supplementary Fig. 2), 
whereas the chloroquine-containing formulation, DPP80-CQ did (Figs. 5 
and 6). The lack of correlation between in vitro and in vivo transfection 
results has been widely reported as it is a context-dependent matter [12]. 
 
Based on previous physicochemical and in vitro biological results, we 
were enthusiastic to perform a preliminary in vivo study to evaluate the 
transfection efficiency of our formulations, DPP80-CQ in particular, in rat 
retinae after subretinal (Fig. 5) and intravitreal injections (Fig. 6). 
Subretinal injection is a well-known clinical viable route to deliver genetic 
material to the eye. It enables direct contact of the injected nucleic acids 
with the outer retinal layers, photoreceptors and RPE cells. Noteworthy, 
clinical trials to treat many inherited retinal diseases such as LCA type 2 use 
subretinal injection [41]. However, it is less desirable than the IV route due 
to the possible complications such as retinal detachment or the localized 
effect around the site of injection. Generally, intravitreal injection is more 
widely applicable in the clinical practice due to its ability to deliver genetic 
materials to a larger retinal surface and advantages of less surgical trauma 
compared to the SR route [42]. 
 
Subretinal administration allows direct contact of genetic material 
with RPE cells and outer layer of the retina. Although this route of 
administration is highly effective to locally transfect cells close to the site of 
the injection, the occasionally observed side effects, related to this invasive 
route, such as retinal detachment, hemorrhages or alterations in RPE cells 
can hamper its practice [43]. In any case, subretinal injections have been 
widely used on clinical trials to treat some devastating genetic disorders of 
the retina reporting excellent outcomes [44]. In addition, the recently 
FDA/EMA-approved Luxturna medicine to deliver healthy copies of the 
RPE65 gene to the retina is administered by subretinal injection. In our in 
vivo experiments, after subretinal administration of nioplexes, we observed 
localized EGFP expression, mainly in some photoreceptor and RPE cells, 
close to the injection site. Transfection at this level can have clinical 
relevance because mutations of>200 genes in RPE cells/photoreceptors are 
related to relevant genetic disorders of the retina such as; Leber congenital 
amaurosis, retinitis pigmentosa, and Stargardt disease, to name just a few 
ones [45].  
 
Compared to subretinal injection, intravitreal injection represents an 
interesting alternative to deliver genetic material to the back of the eye, 
and therefore to access retinal structure. It is a less invasive route, more 
easily to perform, and higher doses can be delivered [46]. Consequently, 
large retinal surfaces can be transfected by this route of administration 
[47]. When we administered 4 μl of DPP80-CQ nioplexes by intravitreal 
injection, the inner layers of the retina (GCL and INL) were mainly 
transfected as observed in Fig. 6. (white and yellow arrows, respectively). 
Transfection at this level can be of clinical relevance in treatment of 
devastating ocular pathologies that compromise the function of ganglion 
cells as glaucoma [48]. Interestingly, EGFP expression was also discerned in 
the OPL (Fig. 6-C, blue arrows) which suggests that nioplexes partially 
diffused, not only through the vitreous where they were administered, but 
also through the inner retinal layers until reach the OPL. Transfection of the 
outer layers of the retina by intravitreal administration of non-viral vectors 
represents a great challenge for the scientific community, since can avoid 
the subretinal injections and the corresponding side effects commonly 
associated to such injection. 
 
Unfortunately, chloroquine, like other endolytic agents, has been 
found to be cytotoxic in several pre-clinical or clinical trials [49]. 
Chloroquine passes the blood-retinal barrier and is toxic to the retina. 
Nevertheless, such retinal toxicity is related to large doses and longterm 
use of chloroquine [50]. In this study, at 10/1 cationic lipid /DNA mass 
ratio, the final concentration of chloroquine was only 25 μg/ml which did not 
induce any significant cytotoxicity in accordance with Chen et al, [36]. The 
affinity of retinal cells to the modified salt form of the cationic lipid, in 
addition to the favorable properties of P and P80, along with the effect of 
chloroquine, raise the possibility to target different retinal cell layers safely 
and effectively after both subretinal and intravitreal administrations. 
 
 
5. Conclusions 
 
The addition of chloroquine to a niosome formulation retained its 
functionality in vitro, but most importantly, enhanced its transfection ability 
in vivo. This work highlights the use of chloroquine as a built-in component 
in the gene delivery vehicles to evade its toxicity and to provide new 
insights into the future of retinal gene therapy. 
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